A Phase I Dose-Escalation Study of Erlotinib in Combination With Dasatinib in Subjects With Advanced Cancer. Companion Study to Umbrella Protocol 2007-0638.
The Phase I dose-escalation study of erlotinib in combination with dasatinib targets advanced cancer patients who are refractory to standard therapies. Given the established market presence of both drugs—erlotinib (Tarceva) for lung and pancreatic cancers and dasatinib (Sprycel) for leukemias—this combination therapy could potentially expand treatment options for patients with EGFR mutations or resistance. The study's focus on identifying the maximum tolerated dose (MTD) and safety profile may provide critical data for future clinical development and regulatory submissions. The competitive landscape includes other combination therapies targeting similar patient populations, necessitating a thorough evaluation of clinical outcomes and market positioning.
Indication: Advanced Cancer
Modality: small molecule
Target: Epidermal Growth Factor Receptor (EGFR) and BCR-ABL fusion protein
Sponsor: M.D. Anderson Cancer Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Epidermal Growth Factor Receptor (EGFR) and BCR-ABL fusion protein
View original source fields
Condition raw: Advanced Cancer
Condition normalized: Advanced Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Epidermal Growth Factor Receptor (EGFR) and BCR-ABL fusion protein
Target normalized: Epidermal Growth Factor Receptor (EGFR) and BCR-ABL fusion protein